These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 39052471)

  • 1. Reducing Tacrolimus Levels to Improve Cognitive Function in Kidney Transplant Recipients.
    Bigotte Vieira M
    Kidney360; 2024 Jul; 5(7):936-937. PubMed ID: 39052471
    [No Abstract]   [Full Text] [Related]  

  • 2. Bioequivalence between innovator and generic tacrolimus in liver and kidney transplant recipients: A randomized, crossover clinical trial.
    Alloway RR; Vinks AA; Fukuda T; Mizuno T; King EC; Zou Y; Jiang W; Woodle ES; Tremblay S; Klawitter J; Klawitter J; Christians U
    PLoS Med; 2017 Nov; 14(11):e1002428. PubMed ID: 29135993
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tacrolimus once-daily formulation in the prophylaxis of transplant rejection in renal or liver allograft recipients: a viewpoint by Sander Florman.
    Florman S
    Drugs; 2007; 67(13):1944. PubMed ID: 17722964
    [No Abstract]   [Full Text] [Related]  

  • 4. Tacrolimus prolonged release (Envarsus®): a review of its use in kidney and liver transplant recipients.
    Garnock-Jones KP
    Drugs; 2015 Feb; 75(3):309-20. PubMed ID: 25613762
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of tacrolimus: clinically relevant aspects.
    Undre NA; Stevenson P; Schäfer A
    Transplant Proc; 1999 Nov; 31(7A):21S-24S. PubMed ID: 10576037
    [No Abstract]   [Full Text] [Related]  

  • 6. Clinical influencing factors for daily dose, trough level, and relative clearance of tacrolimus in renal transplant recipients.
    Hu RH; Lee PH; Tsai MK
    Transplant Proc; 2000 Nov; 32(7):1689-92. PubMed ID: 11119894
    [No Abstract]   [Full Text] [Related]  

  • 7. Two Decades of Tacrolimus in Renal Transplant: Basic Science and Clinical Evidences.
    Shrestha BM
    Exp Clin Transplant; 2017 Feb; 15(1):1-9. PubMed ID: 27938316
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tacrolimus Intrapatient Variability on Graft Outcomes in Adherent Renal Transplantation Patients: A Cross-Sectional Study.
    Nafar M; Keshtkari S; Ziaie S; Firouzan A; Borumandnia N; Dalili N; Poorrezagholi F; Samadian F; Samavat S
    Iran J Kidney Dis; 2024 May; 18(3):187-194. PubMed ID: 38904339
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical and genetic factors affecting tacrolimus trough levels and drug-related outcomes in Korean kidney transplant recipients.
    Kim IW; Moon YJ; Ji E; Kim KI; Han N; Kim SJ; Shin WG; Ha J; Yoon JH; Lee HS; Oh JM
    Eur J Clin Pharmacol; 2012 May; 68(5):657-69. PubMed ID: 22183771
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Epidemiologic Burden of Tacrolimus Variability among Kidney Transplant Recipients in the United States.
    Shah PB; Ennis JL; Cunningham PN; Josephson MA; McGill RL
    Am J Nephrol; 2019; 50(5):370-374. PubMed ID: 31553982
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Conversion to tacrolimus in case-problem kidney transplant recipients under cyclosporine-based immunosuppression.
    Martins L; Henriques AC; Dias L; Sarmento AM; Pereira MC; Guimaräes S
    Transplant Proc; 2000 Dec; 32(8):2636-8. PubMed ID: 11134735
    [No Abstract]   [Full Text] [Related]  

  • 12. Sirolimus in combination with tacrolimus or mycophenolate mofetil for minimizing acute rejection risk in renal transplant recipients--a single center experience.
    El-Sabrout R; Delaney V; Qadir M; Butt F; Hanson P; Butt KM
    Transplant Proc; 2003 May; 35(3 Suppl):89S-94S. PubMed ID: 12742474
    [No Abstract]   [Full Text] [Related]  

  • 13. No Apparent Influence of Nonadherence on Tacrolimus Intrapatient Variability in Stable Kidney Transplant Recipients.
    Gokoel SRM; Zwart TC; Moes DJAR; van der Boog PJM; de Fijter JW
    Ther Drug Monit; 2020 Oct; 42(5):702-709. PubMed ID: 32941396
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tacrolimus: a further update of its use in the management of organ transplantation.
    Scott LJ; McKeage K; Keam SJ; Plosker GL
    Drugs; 2003; 63(12):1247-97. PubMed ID: 12790696
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tacrolimus once-daily formulation: in the prophylaxis of transplant rejection in renal or liver allograft recipients.
    Cross SA; Perry CM
    Drugs; 2007; 67(13):1931-43. PubMed ID: 17722962
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New formulations of tacrolimus and prevention of acute and chronic rejections in adult kidney-transplant recipients.
    Jouve T; Rostaing L; Malvezzi P
    Expert Opin Drug Saf; 2017 Jul; 16(7):845-855. PubMed ID: 28494654
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacogenetic vs. concentration-controlled optimization of tacrolimus dosing in renal allograft recipients.
    Kuypers DR
    Clin Pharmacol Ther; 2010 Nov; 88(5):595-6; author reply 597. PubMed ID: 20664539
    [No Abstract]   [Full Text] [Related]  

  • 18. Pharmacokinetic interaction between tacrolimus and amlodipine in a renal transplant child.
    Zhao W; Baudouin V; Fakhoury M; Storme T; Deschênes G; Jacqz-Aigrain E
    Transplantation; 2012 Apr; 93(7):e29-30. PubMed ID: 22450597
    [No Abstract]   [Full Text] [Related]  

  • 19. Impact of Protease Inhibitor-Based Antiretroviral Therapy on Tacrolimus Intrapatient Variability in HIV-Positive Kidney Transplant Recipients.
    Cooper M; Dunne I; Kuten S; Curtis A; Graviss EA; Nguyen DT; Hobeika M; Gaber AO
    Transplant Proc; 2021 Apr; 53(3):984-988. PubMed ID: 33246588
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tacrolimus variability is associated with de novo donor-specific antibody development in pediatric renal transplant recipients.
    Solomon S; Colovai A; Del Rio M; Hayde N
    Pediatr Nephrol; 2020 Feb; 35(2):261-270. PubMed ID: 31732803
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.